A1 Refereed original research article in a scientific journal

Development of 68Ga-Labeled Hepatitis E Virus Nanoparticles for Targeted Drug Delivery and Diagnostics with PET



Authors: Lambidis Elisavet, Chen Chun-Chieh, Baikoghli Mo, Imlimthan Surachet, Khng You C, Sarparanta Mirkka, Cheng R Holland, Airaksinen Anu J

Publication year: 2022

Journal: Molecular Pharmaceutics

Journal name in source: Molecular pharmaceutics

Journal acronym: Mol Pharm

Volume: 19

Issue: 8

First page : 2971

Last page: 2979

ISSN: 1543-8384

eISSN: 1543-8392

DOI: https://doi.org/10.1021/acs.molpharmaceut.2c00359

Web address : https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.2c00359

Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/176581895


Abstract
Targeted delivery of diagnostics and therapeutics offers essential advantages over nontargeted systemic delivery. These include the reduction of toxicity, the ability to reach sites beyond biological barriers, and the delivery of higher cargo concentrations to diseased sites. Virus-like particles (VLPs) can efficiently be used for targeted delivery purposes. VLPs are derived from the coat proteins of viral capsids. They are self-assembled, biodegradable, and homogeneously distributed. In this study, hepatitis E virus (HEV) VLP derivatives, hepatitis E virus nanoparticles (HEVNPs), were radiolabeled with gallium-68, and consequently, the biodistribution of the labeled [68Ga]Ga-DOTA-HEVNPs was studied in mice. The results indicated that [68Ga]Ga-DOTA-HEVNPs can be considered as promising theranostic nanocarriers, especially for hepatocyte-targeting therapies.

Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.


Last updated on 2024-26-11 at 11:51